Clinical Trials for Somatostatinoma
Clinical trials are research studies conducted in an effort to improve overall patient health and care.
Each trial involves running supervised tests to determine the effectiveness and safety of new drugs, procedures and/or devices with the aim of answering scientific questions about a disease or condition.
Risks and side-effects are also evaluated during these trials with results ranging from being unpleasant, with side effects such as headaches, to more serious or even life-threatening risks.
A clinical trial may be separated into phases, or steps, with each step designed to answer a separate research question. This maybe reflected in the trial name.
A brief description of each phase:
- Phase I: Usually designed to evaluate safety, determine a safe dosage range, and identify side effects on a small group of patients.
- Phase II: If Phase I is successful, the trial is then repeated with a larger group to further evaluate its effect and safety.
- Phase III: Trials are conducted on an ever larger group and are compared with the best current treatment while gathering more information on effect and safety.
- Phase IV: These studies monitor long-term side effects after the treatment has been marketed.
Clinical Trials data for Somatostatinoma is grouped into the following categories:-
The format for each of the following is:
- The name of the trial,
- followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
- followed by a list of drug/s, if any, used in the trial
ClinicalTrials.gov has listed the following trials for Somatostatinoma:
- PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors - This study has been completed (Current: 23 Nov 2006) - PS-341
- Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - ecteinascidin 743
- Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - indium In 111 pentetreotide
- Penclomedine in Treating Patients With Solid Tumors or Lymphoma - This study has been completed (Current: 23 Nov 2006) - penclomedine
- Decitabine in Treating Patients With Melanoma or Other Advanced Cancer - This study has been completed (Current: 23 Nov 2006) - decitabine
- Combination Chemotherapy in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - fluorouracil,leucovorin calcium,topotecan
- Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - interferon alfa,interleukin-12
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy - This study is currently recruiting patients (Current: 23 Nov 2006) - antineoplaston A10,antineoplaston AS2-1
- Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors - This study has been completed (Current: 23 Nov 2006) - irinotecan,LY231514
- Combination Chemotherapy in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - fluorouracil,leucovorin calcium,SCH 66336
- Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - amifostine,carboplatin,cyclophosphamide,sargramostim
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of the HER2/Neu Protein - This study is no longer recruiting patients (Current: 23 Nov 2006) - interleukin-12,trastuzumab
- Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer - This study has been completed (Current: 23 Nov 2006) - R115777,R115777/trastuzumab,trastuzumab
- Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum - This study has been completed (Current: 23 Nov 2006) - floxuridine,leucovorin calcium,oxaliplatin
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - octreotide,yttrium Y 90 SMT 487
- Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - thalidomide
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors - This study has been suspended (Current: 23 Nov 2006) - gefitinib
- FR901228 in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - FR901228
- CCI-779 in Treating Patients With Progressive Metastatic Neuroendocrine Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - temsirolimus
- Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer - This study is currently recruiting patients (Current: 23 Nov 2006) - melphalan
- Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors - This study has been suspended (Current: 23 Nov 2006) - bevacizumab,sorafenib tosylate
- Sorafenib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - sorafenib
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - bevacizumab,fluorouracil,leucovorin calcium,oxaliplatin
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors - This study is not yet open for patient recruitment (Current: 23 Nov 2006) - octreotide acetate,vatalanib
- Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma - This study is currently recruiting patients (Current: 23 Nov 2006) - interferon alfa-2b,sodium stibogluconate
The format for each of the following is:
- The drug,
- followed by the name of the trial,
- followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
ClinicalTrials.gov has listed the following drugs in trials for Somatostatinoma:
The trial data on this page has been sourced from
